{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["masofaniten (EPI-7386)","enzalutamide","androgen deprivation therapy"]],"indication":"treatment-naïve metastatic hormone-sensitive prostate cancer","name":"EXTRA-PC","nct_id":"NCT06312670","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=extra-pc-nct06312670. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"EPI-7386 at 600 mg twice daily orally with standard of care Enzalutamide at 160 mg, once daily, orally for 36 months of treatment (11 cycles).","label":"EPI-7386 + Enzalutamide","type":"EXPERIMENTAL"}],"collaborators":["ESSA Pharma Inc."],"completion_date":{"date":"2025-01-09","type":"ACTUAL"},"conditions":["Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","Prostate Cancer","Prostate Adenocarcinoma"],"enrollment":{"count":13,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"EPI-7386","otherNames":[],"type":"DRUG"},{"name":"Enzalutamide","otherNames":[],"type":"DRUG"},{"name":"Androgen Deprivation Therapy (ADT)","otherNames":[],"type":"DRUG"}],"last_update":"2025-05-29","lead_sponsor":"Pedro Barata, MD, MSc","official_title":"Phase 2 Trial Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-01-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Biochemical response rate","timeFrame":"Post-intervention at Week 4"},{"measure":"PSA progesterone-free survival (PFS)","timeFrame":"Post-intervention at Week 4"},{"measure":"Radiographic PFS (rPFS)","timeFrame":"Post-intervention at Week 4"},{"measure":"ORR (confirmed)","timeFrame":"Post-intervention at Week 4"}],"references":[{"citation":"Jang A, Fowler P, Helminiak K, Kumar HLS, Pasucal J, Delong V, Zhong JY, Jindal T, Grier AL, Patel RR, Hislop M, Cesano A, Villaluna K, Younginger B, Wolff K, Richey K, Bray J, Garcia H, Adamowicz T, Reese A, Nizam A, Gupta S, Wee CE, Margevicius S, Fu P, Mendiratta P, Sheng IY, Brown JR, Garcia JA, Barata PC. EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naive metastatic hormone-sensitive prostate cancer. Oncologist. 2026 Jan 17;31(2):oyaf434. doi: 10.1093/oncolo/oyaf434.","pmid":"41467749","type":"DERIVED"}],"start_date":{"date":"2024-05-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT06312670"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/extra-pc-nct06312670"}